How Glycans Predict Disease Years Before Symptoms Appear

Most standard health tests behave like lagging indicators: they confirm what has already gone wrong, usually once damage has accumulated or symptoms have appeared. Glycans behave differently. IgG glycosylation, the sugar structures attached to antibodies, shifts measurably years before a disease becomes symptomatic, functioning less like a diagnostic result and more like a dashboard warning light that flags trouble while there is still time to act.

Glycans sit at the intersection of genetics and environment. More than 600 genes shape how they are built, yet their composition is also heavily influenced by lifestyle and environmental exposure, acting through epigenetic regulation of those genes. That dual sensitivity is exactly why they can register immune and metabolic drift long before conventional markers catch up, and it is worth keeping in mind as the leading indicator throughout what follows.

Want the fuller picture of what glycans are and what they reveal about you? Read Glycans: The Sugars That Reveal Your Biological Age and Immune Health.

The silent window: how far ahead can glycans see trouble coming?

For type 2 diabetes, a prospective study following 534 initially disease-free adults found that plasma N-glycan patterns diverged from healthy controls up to 10 years before a diagnosis of insulin resistance or type 2 diabetes was made, deteriorating continuously the closer participants got to diagnosis. A model built on these glycan traits distinguished future cases from controls with a discriminative accuracy (AUC) of 0.77, in people who had no reported symptoms at the time of testing.

Cardiovascular disease shows a comparable pattern. In two nested case-control studies, baseline IgG glycan profiles measured years in advance were associated with future cardiovascular events. Each standard-deviation increase in an IgG glycan score was linked to roughly double the risk in the primary-prevention cohort, and the association held up to nearly five years of follow-up in a secondary-prevention validation cohort of patients with existing coronary heart disease.

"We identified that this GlycA signal, measured among 28,000 women in the Women's Health Study who we had followed for over 20 years, predicted risk of future heart attack and future stroke in these women, even followed up to 20 years later. That was really the first report of its relationship to cardiovascular events."
— Prof. Samia Mora, Professor of Medicine, Harvard Medical School; Director, Center for Lipid Metabolomics, Brigham and Women's Hospital

Rheumatoid arthritis shows the longest lead time studied so far. Across two prospective cohorts totalling almost 15,000 people, lower IgG galactosylation was associated with a future RA diagnosis made up to 10 years later, with the glycan difference already present and stable long before the median 4.3 years to diagnosis. The body mistakenly produces antibodies that target its own proteins, known as anti-citrullinated protein antibodies, or ACPAs, and it is specifically this fraction of the IgG pool where the aberrant glycosylation resides. Notably, the extent of the glycosylation change tracks disease severity, and improvement of the IgG N-glycosylation profile during pregnancy has been associated with improvement of RA symptoms, an early sign that the same signal that warns of disease can also register when a person's biology is trending the other way.

Across metabolic, cardiovascular, and autoimmune disease, the pattern repeats. The glycan signal moves first, and the clinical diagnosis arrives last, which is the entire premise of treating it as a leading indicator rather than a confirmatory one.

Actionable foreknowledge: trending toward disease is not the same as having it

This is where predictive data earns its name. A diagnostic test answers a narrow question after the fact: does this person currently have the disease? A predictive glycan signal answers a different, earlier question: is this person's biology currently trending toward disease, years before any diagnostic criteria would be met? The distinction is practical, not academic. "You are at risk" based on family history or a single risk factor is a static statement that does not change. "Your IgG glycosylation pattern is currently shifting in the direction associated with future cardiometabolic or autoimmune disease" is a dynamic, trackable one, and dynamic signals are the ones a person can actually act on. For an individual, that turns an abstract worry into something concrete enough to track and change. For a clinician, the same shift moves the conversation with a patient away from a one-time risk disclosure and toward an ongoing, measurable trend line.

Why the signal moves: genes set the range, environment sets the trend

None of this works as an early-warning system if glycans were fixed at birth. Unlike proteins, glycans are not produced from a genetic template, so their day-to-day composition stays responsive to environmental exposure long into adulthood.

"We're very much interested in both genes and the environment, and their interaction, to improve the prediction of disease, so that we can either prevent or delay the onset of these diseases later in life."
— Prof. Riccardo Marioni, University of Edinburgh

Aberrant glycosylation is not unique to the three diseases above, either. In a mouse model, removing a key enzyme responsible for processing N-glycans triggered an autoimmune disease similar to human lupus, while a genome-wide analysis in humans identified glycosylation-related genes independently associated with the same condition. Similar patterns appear in multiple sclerosis. And genetics alone rarely tells the whole story: genes associated with inflammatory bowel disease explain only about 20 to 25% of its heritability, leaving air pollution, diet, smoking, antibiotics, and gut bacteria to account for much of what actually drives disease severity and progression, precisely the kind of environmental input that shows up first in the glycome.

That responsiveness has been demonstrated directly at the molecular level too: in cervical cancer cells, treatment with epigenetic inhibitors altered the composition of surface glycans by up to 20%, and every one of those changes reversed once the inhibitor was removed. A further layer of interaction happens through "good" microorganisms living on the mouth and gut, where a healthy exchange helps guard against inflammatory and autoimmune disease. Taken together, these findings support what researchers call the dynamic glycoform model of IgG glycosylation: the idea that glycosylation is continuously shaped and reshaped by the immediate environment rather than fixed by inheritance. That is what makes the early-warning window actionable rather than just informative. A signal that responds to environment is a signal that can be moved.

Proactive intervention: using the lead time, not just watching it

A ten-year lead time is only valuable if it changes what someone does with it. Because IgG glycosylation responds to lifestyle and, in some cases, to targeted pharmaceutical or hormonal intervention, tracking it over time turns a one-off risk estimate into a feedback loop: intervene, retest, and see whether the inflammatory trend is reversing, exactly the kind of longitudinal, intervention-responsive marker a functional medicine approach is built around.

"The hope would be that if we can measure these ages before the disease emerges, we can prescribe interventions earlier and earlier, hopefully interventions without side effects, like exercising more or drinking less, and really motivate people to do those in a targeted way that reflects their susceptibilities and their lifestyles."
— Dr. Peter Joshi, Chief Scientist, Humanity Health; tenured academic, University of Edinburgh

Retesting cadence differs by intervention type. Pharmaceutical or HRT-driven changes tend to register within three to four months, while lifestyle changes such as diet, exercise, and stress reduction typically take six to twelve months to show up. Either way, the same biomarker that flagged the early drift can confirm whether the trend has reversed, well before any of the three diseases discussed above would otherwise be diagnosed. For clinics running longevity or corporate wellness programmes, the same signal that flags early risk also works as a check on whether an intervention is actually shifting a patient's trajectory, rather than just their subjective sense of progress.

For health-conscious individuals and functional medicine practitioners working years ahead of a possible diagnosis, this reframes what a blood-based biomarker can offer. This early-warning signal, the same IgG N-glycosylation pattern behind the studies above, is what GlycanAge measures from a simple finger-prick sample, tracking immune-driven inflammation over time so a trend can be caught and addressed while the silent window is still open.

Ready to see where your own immune-glycan profile stands? Shop GlycanAge Tests.

External sources

• Cvetko A, Mangino M, Tijardovic M, Kifer D, Falchi M, Keser T, et al. Plasma N-glycome shows continuous deterioration as the diagnosis of insulin resistance approaches. BMJ Open Diabetes Res Care. 2021 Sep;9(1):e002263. DOI: 10.1136/bmjdrc-2021-002263. Link: https://pubmed.ncbi.nlm.nih.gov/34518155/

• Hoshi RA, Plavsa B, Liu Y, Trbojevic-Akmacic I, Glynn RJ, Ridker PM, et al. N-glycosylation profiles of immunoglobulin G and future cardiovascular events. Circ Res. 2024 Mar;134(5):e3-e14. DOI: 10.1161/CIRCRESAHA.123.323623. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10923145/

• Gudelj I, Salo PP, Trbojevic-Akmacic I, Albers M, Primorac D, Perola M, Lauc G. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt A):2034-2039. DOI: 10.1016/j.bbadis.2018.03.018. Link: https://pubmed.ncbi.nlm.nih.gov/29572115/

• van de Geijn FE, Wuhrer M, Selman MH, Willemsen SP, de Man YA, Deelder AM, Hazes JM, Dolhain RJ. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther. 2009;11(6):R193. DOI: 10.1186/ar2892. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3003510/

• Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity. 2007 Aug;27(2):308-320. DOI: 10.1016/j.immuni.2007.06.008. Link: https://pubmed.ncbi.nlm.nih.gov/17681821/

• Lauc G, Huffman JE, Pucic M, Zgaga L, Adamczyk B, Muzinic A, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9(1):e1003225. DOI: 10.1371/journal.pgen.1003225. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3561084/

• Cvetko A, Kifer D, Gornik O, Klaric L, Visser E, Lauc G, Wilson JF, Stambuk T. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential. Biomedicines. 2020 Oct;8(10):410. DOI: 10.3390/biomedicines8100410. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7599553/

• Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015 Nov;6:551. DOI: 10.3389/fimmu.2015.00551. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC4629465/

• Horvat T, Dezeljin M, Redzic I, Barisic D, Herak Bosnar M, Lauc G, Zoldos V. Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors. PLoS One. 2013;8(1):e54672. DOI: 10.1371/journal.pone.0054672. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3545996/

• Stambuk T, Klasic M, Zoldos V, Lauc G. N-glycans as functional effectors of genetic and epigenetic disease risk. Mol Aspects Med. 2021 Jun;79:100891. DOI: 10.1016/j.mam.2020.100891. Link: https://pubmed.ncbi.nlm.nih.gov/32861467/